盤中異動 | 阿裏再漲超3%,今年已飆漲超31%,股價創半年新高
1月11日訊,港股$阿裏巴巴-SW(09988.HK)$漲超3%,成交超10億港元,股價創2022年7月以來新高。隔夜美股$阿裏巴巴(BABA.US)$收漲3.65%報114.88美元。
消息面上,杭州市政府與阿裏巴巴集團簽訂全面深化戰略合作協議。據瞭解,杭州支持平臺經濟規範健康發展的具體措施已在制定中。另外,杭州市委書記劉捷調研螞蟻集團。
中信證券發佈研究報告稱,維持阿裏巴巴-SW“買入”評級,預計去年12月季度GMV將同比下滑約5%,預計CMR同比下滑9%,CMR和GMV的增速GAP環比將有所上升,目標價142港元,維持對其中長期數字化商業服務能力相對樂觀的態度。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.